Bridgette
Dont want to be a killjoy,but I disagree with you.
The fact is that Relenza has never been a commercial success.
EVERY year many millions of people throughout the world get flu.
Tens of thousands die from it.
Despite this, the public have not taken to Relenza.
( This is the reason for my tongue in cheek posts recently about dosing birds with it...It needs a new market ! )
The main reason in my opinion that it hasn't taken on is because it is too complicated to use.
The inhaler device is an design & mechanical masterpiece.
But therein lies the problem.
One almost needs an engineering degree to figure it out.
The last thing a person who has flu & feels lousy & is not thinking too clearly needs, is to be confronted with this puzzle.
Much easier to take a tablet or capsule, which is why Tamiflu is more popular.
As far as R & D goes, Bioita would be an absolute minnow compared to the R & D conducted by GSK.
I would imagine they would prefer NOT to do R & D anyway if they could commercially exploit other peoples.
Bendigo
- Forums
- ASX - By Stock
- BTA
- gsk takeover bid - $1.00?
gsk takeover bid - $1.00?, page-3
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online